What's in Lineage Cell Therapeutics, Inc.'s pipeline?

Lineage Cell Therapeutics, Inc. has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Lineage Cell Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Diakonos Oncology Corporation, Lisata Therapeutics, Inc., Steminent Biotherapeutics Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lineage-cell-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Lineage Cell Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Lineage Cell Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Diakonos Oncology Corporation · 1 shared drug class
Lisata Therapeutics, Inc. · 1 shared drug class
Steminent Biotherapeutics Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lineage Cell Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Lineage Cell Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lineage-cell-therapeutics-inc. Accessed 2026-05-16.